Natural Treatments End Height Loss in Aging

ask_dr_braverman
Click here to get a FREE consultation on your brain health and your body's oldest parts today!
contact_us

Make an appointment
Tel: 1.888.304.PATH
Tel: 212.213.6155
info@pathmed.com

Join our mailing list and receive
your FREE guide: "How to Get
Younger and Healthier NOW"
View Newsletter Archives

Natural Treatments End Height Loss in Aging

December 1st, 2009

Diseases associated with low bone density result when the rate at which bone resorption is faster than the rate of bone formation. Bone resorption is a natural process within the body in which minerals are released from the breakdown of bone by cells called osteoclasts. Conversely, bone formation is the development of new bone tissue by cells called osteoblasts. Usually, the two processes are maintained in a delicate balance, but sometimes, bone is broken down faster than it is formed and the balance is disrupted causing diseases like osteoporosis, Paget’s disease, and fibrous dysplasia.

Luckily, doctors have a repertoire of tools to repair such a disrupted balance. One tool is parathyroid hormone (PTH), which enhances bone formation. Another tool is a certain class of drugs called biphosphonates. Biphosphonates inhibit the function of osteoclasts thus decreasing bone resorption. Of course, it is natural to think that the effects of both bisphosphonates and PTH together on low bone density diseases would be additive. This is to say that one would heal faster and more effectively if he/she underwent both treatments than if he/she were to undergo just one of the two treatments.  However this is not the case! 

In a study at the Hospital for Special Surgery, it was found that biphosphonates like alendonate (the active ingredient of Flomax) actually hinder the effects of PTH. How? PTH enhances bone formation by producing a signal that activates cells to build to new bone tissue. Biphosphonates, however, block the parathyroid hormone’s ability to produce this signal thus hindering the overall effects of PTH.

References

Issack PS, Laureman MH, Helfelt DL, Doty SB, Lane JM. Alendronate Inhibits PTH (1-34)-induced Bone Morphogenetic Protein Expression in MC3T3-E1 Preosteoblastic Cells. HSS J. 2007; 3(2): 169-72.

Dr. Eric Braverman
Please note:
Information on this web site is provided for informational purposes only and is not intended as a substitute for the advice provided by your physician or other healthcare professional. You should not use the information on this web site for diagnosing or treating a health problem or disease, or prescribing any medication or other treatment.